The factor that is most relevant and strongly associated with the clinical course of multiple
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …

Background Multiple sclerosis typically has onset in young adults and new disease activity
diminishes with age. Most clinical trials of disease-modifying therapies for multiple sclerosis …

Importance A recent randomized clinical trial concluded that discontinuing medium-efficacy
therapy might be a reasonable option for older patients with nonactive multiple sclerosis …

Objective To evaluate the outcomes of immunosuppressive therapy (IST) discontinuation in
patients with neuromyelitis optica spectrum disorder (NMOSD) after a sustained remission …

Background Nonadherence to disease-modifying drugs (DMDs) for multiple sclerosis (MS)
is associated with poorer clinical outcomes, including higher rates of relapse and disease …

Aging is associated with a progressive decline of innate and adaptive immune responses,
called immunosenescence. This phenomenon links to different multiple sclerosis (MS) …

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-
modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding …